Minoxidil vs PP405
FDA Approved vs Emerging
compatible Researched · 90% Different mechanisms of action. Minoxidil promotes vasodilation and extends the anagen phase through potassium channel opening, while PP405 reactivates dormant stem cells via metabolic reprogramming. No known contraindications for combined use.
Molecular Data
Minoxidil PP405
Weight 209.25 Da ~300-400 Da (exact structure not fully published)
Half-life ~4 hours (oral); topical effects persist significantly longer due to local tissue retention Topical application; exact pharmacokinetics not published
Type Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine) Small molecule mitochondrial pyruvate carrier (MPC) inhibitor
Key Benefits
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
PP405
01 Novel non-hormonal mechanism of action targeting hair follicle stem cell metabolism
02 Directly addresses the root cause of follicle dormancy rather than downstream hormonal effects
03 Potentially effective regardless of androgen status, broadening the treatable population
04 Topical application (0.05% gel) limits systemic exposure
05 Phase 2a results demonstrated increased hair count and thickness
06 Compatible with existing hair loss treatments (finasteride, minoxidil) for combination therapy
07 No known sexual or hormonal side effects based on available trial data
Side Effects
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
PP405
Scalp irritation at the application site
Application site reactions (redness, dryness, itching)
Contraindications
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Known hypersensitivity to PP405 or any component of the gel formulation
Full contraindication profile has not been established (investigational drug)
Pregnant or breastfeeding women should avoid use until safety data is available
Research Evidence
Minoxidil PP405
Status FDA Approved Emerging
References 5 studies 2 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.